ReShape Lifesciences Inc

ReShape Lifesciences — EnteroMedics — Investor Presentation (July 2017)

27 slides from ReShape Lifesciences's investor presentation, Jul 26, 2017

  1. Slide 1: Forward-looking statements

    2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “f

  2. Slide 2: Addressing $1.5 billion/year surgical device market

    Addressing $1.5 billion/year surgical device market¹ Safe, minimally invasive, anatomy preserving solutions with durable outcomes Growing pipeline via continued acquisition and development 1. Global Bariatric Surgery Devices Market Analysis and Trends, Industry Forecast to 2025, Accuray Research 3 C

  3. Slide 3: EnteroMedics Company Highlights

    4 EnteroMedics Company Highlights Addressing the Continuum of Care in Obesity Innovative Medical Technologies vBloc® Therapy Gaining Traction Growing Pipeline + Opportunities Data Supporting Coverage Anatomy friendly solutions Minimally invasive (MIS) procedures Reversible/removable devices Strong s

  4. Slide 4: Obesity is Growing in Epidemic Proportions

    5 Obesity is Growing in Epidemic Proportions $1.5B 2025E ~200K3 U.S. Procedures ~800K2 U.S. Procedures $3.8B¹ 2015 20,000,000 patients qualify for obesity surgery. Only 1% receive surgical intervention 2015 – 2025 Projected Growth Drivers Increase in interventions with new procedures and therapies A

  5. Slide 5: High Healthcare Costs of Obesity

    6 High Healthcare Costs of Obesity Obesity is the #1 cause of preventable death in the U.S.A. 70 million adults in the U.S. and 545 million adults worldwide struggle with obesity Global economic impact of obesity was estimated at $2.0 trillion in 2014 Obese adults spend 42% more on healthcare than t

  6. Slide 6: The Challenge of Today's Surgical Solutions for Obesity

    The Challenge of Today’s Surgical Solutions for Obesity SAFETY Are there safety concerns? There is a significant unmet need for a better weight-loss solution Long and short-term safety profiles of many procedures are of concern Many current procedures are highly invasive and/or anatomy altering Only

  7. Slide 7: Meeting Customer and Patient Needs

    Meeting Customer and Patient Needs 8 DESIRABLE SOLUTION INCREASE QUALITY OF LIFE DURABLE WEIGHT LOSS A SAFE SOLUTION An obesity treatment that provides the feeling of fullness with smaller amounts of food, enabling weight loss and reducing the co-morbidities of excess weight A minimally invasive sol

  8. Slide 8: EnteroMedics' Current Portfolio

    EnteroMedics’ Current Portfolio 10 Minimally invasive Durable, sustainable, long-term weight loss solution Manages co-morbidities Non anatomy changing; reversible Safe with low complication rates FDA approved In-house 24/7 Customer service component Lifestyle and nutritional advice for our patients

  9. Slide 9: vBloc Neurometabolic Therapy

    vBloc® Neurometabolic Therapy 11 More than 700 patients implanted to date 16 centers currently implanting Patient can maintain diet choices Non-anatomy-altering and improved quality of life Safe and effective minimally invasive outpatient procedure Proprietary bioelectronic neuroblocking technology

  10. Slide 10: vBloc Clinical Data

    12 vBloc Clinical Data Efficacious Achieves meaningful and sustainable weight loss Safe Low complication rate (3.7%) is significantly safer than any other surgical treatment. Mean %TBL Real-world vBloc ReCharge ReCharge Sham Months Follow-Up Results of vBloc ReCharge FDA Trial % Total Body Weight Lo

  11. Slide 11: vBloc Clinical Evidence: Reduction in Comorbidities

    50% remittance of metabolic syndrome Waist circumference reduced by 7" (~18 cm) Drop in “bad” cholesterol HbA1c (%) reduction of 1.0 point Highly competitive with leading diabetes drugs vBloc Clinical Evidence: Reduction in Comorbidities CLINICAL STUDY PATIENTS AT 1 YEAR vBloc Therapy patients exper

  12. Slide 12: EnteroMedics acquired the Gastric Vest in May 2017

    14 EnteroMedics acquired the Gastric Vest in May 2017 Minimally invasive No stapling, cutting, or removing the stomach Device is removable / reversible Studies show rapid sustainable weight loss in 12 months Currently for investigational use only The Gastric Vest is a thin, implantable-grade silicon

  13. Slide 13: Gastric Vest System Pilot Study Outcomes

    15 Gastric Vest System Pilot Study Outcomes 30.2% Efficacious Pilot study patients achieve gold standard of weight loss at 12 months. Minimally Invasive Vest surgery is laparoscopic and a reversible, anatomy friendly procedure Confidential information. Do not distribute. 12. Schauer et al. N.E.J.M.

  14. Slide 14: Gastric Vest Clinical Evidence: Reduction in Comorbidities

    PILOT STUDY PATIENTS AT 1 YEAR Patients in the Gastric Vest pilot study demonstrated significant improvements in comorbidities HbA1c (%) reduction of 2.1 points Systolic blood pressure decreased 13 mmHg Increase in HDL “good cholesterol” of 29 mg/dL Improvements in co-morbidities yield significant s

  15. Slide 15: vBloc Commercial Strategy

    vBloc Commercial Strategy Multi-tiered strategy converts leads to implants and gains payer attention driving coverage decisions vBloc Institutes 16 centers in U.S. trained and credentialed on vBloc Partners in data collection/publication Payer and employer engagement Employee coverage (where applica

  16. Slide 16: Strategy to Collect vBloc Outcomes Data for Reimbursement

    Strategy to Collect vBloc Outcomes Data for Reimbursement vBloc Now Program (June 2017) Real-world outcomes on over 125 patients from select vBloc institutes Will include co-morbidity improvement data Data to be utilized to support reimbursement ReNew FDA Post-Market Study (August 2017) Five year, 2

  17. Slide 17: Gastric Vest Clinical and Regulatory Path

    Gastric Vest Clinical and Regulatory Path US FDA Study PMA. 200-250 patient pivotal trial with a 12-month weight loss and safety endpoint. Minimum of 2-year follow-up First US PMA implants expected in Q2 2018 with approval estimated Q4 2020, pending FDA review times EU Study: CE Mark trial of 50-100

  18. Slide 18: Driving Coverage and Reimbursement

    Driving Coverage and Reimbursement MULTI-FACETED REIMBURSEMENT STRATEGY TO DRIVE LONG-TERM COVERAGE Physician Demand Surgeons engage commercial payers and MACs Patient Demand vBloc Access program supports patients during prior authorization and appeals Cost Analysis Study and publish economic saving

  19. Slide 19: Intellectual Property

    Intellectual Property 21 Bioelectronic Medicine (vBloc) Broad claim coverage for bioelectronic systems and methods related to neuroblocking, neuromodulation, and neurostimulation technology IP covers indications including obesity, bulimia, pancreatitis, heart rate regulation, and glucose regulation

  20. Slide 20: Strategic Partnership with Galvani Bioelectronics

    Strategic Partnership with Galvani Bioelectronics 22 Confidential information. Do not distribute. Galvani is a joint venture between GlaxoSmithKline and Verily Life Sciences (an Alphabet company) that was established in 2016 to enable the research, development and commercialization of bioelectronic

  21. Slide 21: EnteroMedics Milestones and Objectives

    EnteroMedics Milestones and Objectives Establish vBloc Reimbursement Grow Pipeline Focus on Commercial Use and Outcomes Commercial coverage Publish real-world outcomes and co-morbidity data Complete CE Mark trial for Gastric Vest Complete US PMA trial for Gastric Vest Strategic partnerships and acqu

  22. Slide 22: Financial Snapshot

    Financial Snapshot Key Balance Sheet Metrics Cash as of June 30, 2017 $11.0 M Debt as of June 30, 2017 $0.0 Commercial Unit Placements Full year 2016 63 Six months ended June 30, 2017 50 Capitalization (as of June 30, 2017, in millions) Common Shares Outstanding 8.3 To be issued (BarioSurg) 5.0 Issu

  23. Slide 23: Investment Summary

    Investment Summary 25 Confidential information. Do not distribute. Large, underserved and rapidly expanding market with multiple sub-segments FDA approved vBloc technology gaining commercial traction Growing minimally invasive pipeline for the treatment of obesity via continued acquisition and devel

  24. Slide 24: EnteroMedics Inc. contact details

    EnteroMedics Inc. (NASDAQ:ETRM) 2800 Patton Road St. Paul, MN 55113 Dan Gladney President, Chief Executive Officer & Chairman of the Board 651-634-3089 dwgladney@enteromedics.com

  25. Slide 25: EnteroMedics contact details

    EnteroMedics’ EnteroMedics Inc. (NASDAQ:ETRM) 2800 Patton Road St. Paul, MN 55113, Dan Gladney President, Chief Executive Officer & Chairman of the Board 651-634-3089 dwgladney@enteromedics.com EnteroMedics

  26. Slide 26: Positioning Gastric Vest and vBloc in the Market

    28 Positioning Gastric Vest and vBloc in the Market Alter Anatomy? Diet Restrictions Procedure Type Safety Risks Weight Loss %EWL Procedure Cost By-Pass Yes Severe Laparoscopic Potential for serious complications 65-80% ~$24,000 Sleeve Yes Severe Laparoscopic Potential for serious complications 50-6

  27. Slide 27: Procedure comparison and cost

    Procedure Cost vee severe | Lapaoscoic | Potmtalonser | eseon | ~24000 ves severe | Laparosane | Potnteltorserous | soesy | 518,000 GastricVest Vy FRUEEM ros: | nore | Lapacscapic tow sass $2.00 aw) Vest sr1.000 sand None | Laparoscopic | Erosion nection, | apo, 15,000 Bloc [an | a )aan) a) ea) am N

EnteroMedics — Investor Presentation (July 2017) on 6ix